Pricing
  1. JP-listed companies
  2. Carna Biosciences, Inc.
  3. Financials
  4. Revenue

Carna Biosciences, Inc. (4572)

Market cap
¥7.4B
P/E ratio
-3.5x
Karna Bioscience develops kinase inhibitor drugs and provides drug discovery support services to pharmaceutical companies and research institutions.
SummaryFinancialsDividendsHistorySegmentsOwnershipWorkforce
Period EndRevenue (Million JPY)YoY (%)
Dec 31, 2025579-8.99%
Dec 31, 2024636-60.87%
Dec 31, 20231,626+17.24%
Dec 31, 20221,387-31.27%
Dec 31, 20212,018+78.02%
Dec 31, 20201,133-64.66%
Dec 31, 20193,207+325.00%
Dec 31, 2018755+14.78%
Dec 31, 2017658-18.99%
Dec 31, 2016812-48.28%
Dec 31, 20151,569+156.51%
Dec 31, 2014612-20.70%
Dec 31, 2013771+51.02%
Dec 31, 2012511-13.79%
Dec 31, 2011593

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)
AI Chat